Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionVerition Fund Management LLC
Latest Disclosed Ownership898 shares
Latest Disclosed Value $ 297,121
Verition Fund Management LLC ownership in ALNY / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Verition Fund Management LLC filed a 13F-HR form disclosing ownership of 898 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $297,121 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 4,005 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -77.58% during the quarter. The current value of the position is $262,737 USD.

Verition Fund Management LLC has a history of taking positions in derivatives of the underlying security (ALNY) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ALNY / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 898 -3,107 -77.58 297 -81.34 0.0019
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,005 -13,028 -76.49 1,593 -79.50 0.0063
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,033 11,330 198.67 7,767 317.81 0.0321
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,703 -5,076 -47.09 1,860 -36.12 0.0083
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,779 7,876 271.31 2,911 326.06 0.0136
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,903 -14,565 -83.38 683 -85.78 0.0027
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,468 10,053 135.58 4,804 166.74 0.0242
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,415 3,019 68.68 1,802 174.54 0.0099
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,396 4,396 657 0.0045
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,391 -100.00 0 -100.00
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,391 1,391 246 0.0029
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,827 -100.00 0 -100.00
2023-01-18 2022-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 4,827 4,827 966 0.0108
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,827 4,827 966 0.0109
2022-08-30 2022-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,404 -100.00 0 -100.00
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,404 0
2022-06-02 2022-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,404 -7,334 -75.31 393 -76.21 0.0047
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,404 -7,334 393 0.0047
2022-05-03 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 9,738 8,670 811.80 1,652 717.82 0.0113
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,286 11,218 2,084 0.0135
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,068 1,068 202 0.0018
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,743 -100.00 0 -100.00
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,743 1,743 258 0.0085
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,304 -100.00 0 -100.00
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,304 5,304 611 0.0111
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -12,222 -100.00 0 -100.00
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,222 12,222 887 0.0249
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,436 -100.00 0 -100.00
2018-08-15 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,436 -1,017 -18.65 437 -32.67 0.0267
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,453 5,453 649 0.0483
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -13,296 -100.00 0 -100.00
2017-08-15 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,296 13,296 1,060 0.1030
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,495 -100.00 0 -100.00
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,495 2,691 95.97 574 111.03 0.0667
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,804 -918 -24.66 272 -6.53 0.0610
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,722 3,722 291 0.0411
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-08-30 2022-06-30 13F/A ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 0 0 n/a n/a n/a
2022-06-02 2022-03-31 13F/A ALNYLAM PHARMACEUTICALS COM Put 4,900 0.00 800 -3.73 n/a n/a n/a
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 4,900 800 n/a n/a n/a
2022-05-03 2021-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Put 4,900 831 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.